CENIX BIOSCIENCE Announces Collaboration with Bayer HealthCare AG to Discover and Validate Novel Therapeutic Targets
Dresden, Germany, - Cenix BioScience GmbH (Dresden) today announced a research collaboration with Bayer HealthCare AG (Leverkusen) to rapidly screen through all known human druggable genes using RNA interference (RNAi) to identify and validate new therapeutic drug targets for several disease indications. Using cell-based assays co-developed with Bayer research teams in Wuppertal (Germany) and West Haven (USA), Cenix will apply its proprietary genome-based high throughput (HT) RNAi screening platform over 6,000 genes in less than 9 months.
"Having launched these HT-RNAi research offerings only this summer after years of careful R&D, we have been particularly gratified by the overwhelming market interest, of which this agreement represents a first, important milestone" said Dr Echeverri, CEO and CSO of Cenix BioScience GmbH.
The project will make use of the genome-wide library of siRNA molecules designed by Cenix using its industry-leading algorithms and produced by Ambion, Inc. (Austin, TX, USA). Under the deal, Cenix will receive upfront payments and research funding, and is eligible for downstream milestone payments. Bayer will have the option to obtain all rights to new intellectual property generated by the project.
Most read news
Topics
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic World Cell Analysis
Cell analyse advanced method allows us to explore and understand cells in their many facets. From single cell analysis to flow cytometry and imaging technology, cell analysis provides us with valuable insights into the structure, function and interaction of cells. Whether in medicine, biological research or pharmacology, cell analysis is revolutionizing our understanding of disease, development and treatment options.

Topic World Cell Analysis
Cell analyse advanced method allows us to explore and understand cells in their many facets. From single cell analysis to flow cytometry and imaging technology, cell analysis provides us with valuable insights into the structure, function and interaction of cells. Whether in medicine, biological research or pharmacology, cell analysis is revolutionizing our understanding of disease, development and treatment options.
Last viewed contents
Richard_Evans_Schultes
Grimm's_hydride_displacement_law
Category:Smallpox

More deaths due to air pollution - Air pollution could claim 6.6 million lives by 2050
Riemser Arzneimittel AG Sells Veterinary Business to Ecuphar N.V.
Primary endpoint reached in phase II clinical trial of Active Biotech's substance for oral treatment of multiple sclerosis
Genetic Study to Understand Linkage Between Lead Exposure and Children's Intellectual Development in India - BioServe Partners with Harvard and University of Michigan on Landmark Public Health Study

Vereinigung deutscher Biotechnologie-Unternehmen (VBU) - Frankfurt am Main, Germany
Biogen Idec to acquire Fumapharm AG
Knee_cartilage_replacement_therapy

mobiolab GmbH i. Gr. - Berlin, Germany
